Search
Dipicolinic acid
go.drugbank.com/drugs/DB04267ExperimentalCategories: Compounds used in a research, industrial, or household settingBaicalein
go.drugbank.com/drugs/DB16101Investigationalin the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever). … Baicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets
Categories: Compounds used in a research, industrial, or household settingDibutylphthalate
go.drugbank.com/drugs/DB13716ExperimentalCategories: Compounds used in a research, industrial, or household settingGallium citrate
go.drugbank.com/drugs/DB17893InvestigationalCategories: Compounds used in a research, industrial, or household settingFerrous glycine sulfate
go.drugbank.com/drugs/DB14501ApprovedSynonyms: Iron(II) glycine sulfate, Ferrous (II) Glycine Sulphate ComplexMalic acid
go.drugbank.com/drugs/DB12751InvestigationalMalic acid has been used in trials studying the treatment of Xerostomia, Depression, and Hypertension.
Mixtures: AKE 1100 GLUKOZLU IV SOLOSYONU, 500 ML, AKE 1100 GLUKOZLU IV SOLOSYONU, 1000 MLCHF 4227
go.drugbank.com/drugs/DB05882ExperimentalThe compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. … Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.
Ranirestat
go.drugbank.com/drugs/DB05327InvestigationalIt has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy. … Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels
Peptide YY (3-36)
go.drugbank.com/drugs/DB05004InvestigationalPeptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Elacridar
go.drugbank.com/drugs/DB04881InvestigationalIn many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. … Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors.